Compare PGP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGP | IMUX |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.5M | 188.8M |
| IPO Year | N/A | 2013 |
| Metric | PGP | IMUX |
|---|---|---|
| Price | $8.49 | $14.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 47.6K | ★ 231.4K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.04 | $0.51 |
| 52 Week High | $9.41 | $15.77 |
| Indicator | PGP | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 64.96 |
| Support Level | $8.39 | $0.74 |
| Resistance Level | $8.68 | $15.77 |
| Average True Range (ATR) | 0.18 | 1.18 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 44.37 | 87.18 |
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.